Financial Data and Key Metrics Changes - The company reported weaker financial results for Q3 2025, with a 5% decline in total adjusted EBITDA primarily due to performance in Mexico [6][9] - Adjusted net income was PEN 58 million for the quarter, with FX-neutral consolidated revenue increasing by 1% [9][24] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's top line and EBITDA grew by 9% and 15% respectively, driven by an improving healthcare pricing mix and strong insurance MLR [7][18] - Colombia's revenue increased by 5%, supported by risk-sharing models, while adjusted EBITDA grew by 18% [19][21] - Mexico experienced a 12% revenue decline, although surgery volumes and oncology services showed growth [9][11] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, with a solid growth trajectory [21] - Colombia's revenue share from Nueva EPS decreased from 20% to 13%, indicating successful diversification [19][45] - Mexico's revenue decline was attributed to a slow recovery in volumes and non-operating impacts from system migrations [21][24] Company Strategy and Development Direction - The company aims to capture long-term growth opportunities in Mexico, anticipating a full recovery in 2026 [8][32] - Auna is focusing on enhancing its oncology capabilities and expanding its service offerings in Mexico [16][14] - The partnership with Sojitz is expected to accelerate growth in Mexico while maintaining leverage targets [39][72] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in Mexico but expressed optimism about future growth and recovery [6][32] - The company remains committed to improving its leverage ratio and enhancing shareholder value [27][62] - Management highlighted the resilience of its integrated model and the potential for growth in Peru and Colombia despite external challenges [30][41] Other Important Information - Auna successfully completed a $765 million debt refinancing, improving its debt profile and financial flexibility [27][28] - The company is implementing a new comprehensive IT system to enhance operational efficiency and data management [17][12] Q&A Session Summary Question: Could you explain the rationale for expanding in Mexico and how it aligns with your goal to deleverage Auna? - Management emphasized that Auna is a growth story and sees significant opportunities in Mexico, with the partnership with Sojitz facilitating this growth while maintaining leverage targets [39][40] Question: Do you think a potential change in Colombia's leadership could ease pressures on EPSs? - Management indicated that while political changes may not have immediate effects, there are signs of stabilization in the Colombian healthcare sector [40][45] Question: What key KPIs should be tracked to confirm a tangible recovery in 2026? - Management suggested monitoring occupancy, payer mix, and surgical productivity as key indicators of recovery [61] Question: Could you provide more details around the partnership with Sojitz and the TRECA project? - Management confirmed that the TRECA project is a significant public-private partnership that will enhance Auna's service capabilities in Peru [52][53] Question: How do you plan to increase out-of-pocket sales mix in Mexico? - Management outlined initiatives to aggressively capture out-of-pocket patients through packaged services and improved pricing strategies [80][81]
Auna S.A.(AUNA) - 2025 Q3 - Earnings Call Transcript